Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma
Conditions
Keywords
SYK inhibitor
Brief summary
The primary objective of the study is to evaluate efficacy of entospletinib in participants with relapsed or refractory hematologic malignancies. Participants with the following relapsed or refractory hematologic malignancies will be enrolled into the study: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Interventions
DRUGEntospletinib MM
Entospletinib MM tablet administered orally
DRUGEntospletinib SDD
Entospletinib SDD tablet administered orally
Sponsors
Gilead Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health Organization * For institutions that have Phase 3 or Phase 4 protocols studying idelalisib (Zydelig®) ; individuals with malignancies being studied in these protocols must have failed screening in the respective idelalisib protocol * Prior treatment for lymphoid malignancy requiring treatment for progressive disease * Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy * All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before the start of study drug * Karnofsky performance status of ≥ 60 * Life expectancy of at least 3 months Key
Exclusion criteria
* Known histological transformation from iNHL or CLL to an aggressive form of non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL participant is enrolling in the BCR previously treated cohort * Known active central nervous system or leptomeningeal lymphoma * Presence of known intermediate- or high-grade myelodysplastic syndrome * Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug * Ongoing liver injury * Ongoing or recent hepatic encephalopathy * Ongoing drug-induced pneumonitis * Ongoing inflammatory bowel disease * Ongoing alcohol or drug addiction * Pregnancy or breastfeeding * History of prior allogeneic bone marrow progenitor cell or solid organ transplantation * Ongoing immunosuppressive therapy * Concurrent participation in an investigational drug trial with therapeutic intent NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | Week 16 | PFS rate was assessed by Independent Review Committee (IRC) and defined per standardized criteria (2007 Cheson criteria) (for NHL) and International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (for CLL), as the percentage of participants not experiencing definitive progression or death. Disease progression was defined per standardized criteria as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal immunoglobulin M (IgM) concentration or total serum IgM quantitation. Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL. PFS rate was analyzed using Kaplan-Meier (KM) estimates. |
| PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | Week 24 | PFS rate was assessed by IRC and defined per standardized criteria (2007 Cheson criteria) (for NHL) and IWCLL criteria (for CLL), as the percentage of participants not experiencing definitive progression or death. Disease progression was defined per standardized criteria (2007 Cheson criteria) as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal IgM concentration or total serum IgM quantitation. Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL. PFS rate was analyzed using KM estimates. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | First dose date up to the last dose date plus 30 days (maximum: 78.4 months) | Serum chemistry toxicity at anytime postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase |
| Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | From first dose date until first occurrence of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years) | ORR: percentage of participants with complete response (CR) or partial response (PR) (or very good PR \[VGPR\] or minor response \[MR\] for participants with LPL/WM). Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters of all index lesions, no new lesions; VGPR: \>90% decrease from baseline (DFB) in IgM, and other criteria for CR met; MR: ≥25% but \<50% DFB in IgM, no increase from baseline (IFB) in SPD of lesions, no new lesions. Per IWCLL, CR: lymphocytes (Ly) \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, absolute neutrophil count (ANC) \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, hemoglobin (Hb) \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. |
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | First dose date up to the last dose date plus 30 days (maximum: 78.4 months) | A treatment-emergent Adverse Event (AE) was defined as an AE that occurs in the period from the first dose of study treatment to 30 days after the last dose of study treatment or leads to discontinuation of study treatment. Participants were assessed for AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. |
| Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | From the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years) | TTR was defined as the interval from the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM). Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥ 50% reduction in SPD of the longest diameters of all index lesions, no new lesions; VGPR: \>90% DFB in IgM, and other criteria for CR met; MR: ≥25% but \<50% DFB in IgM, no IFB in SPD of lesions, no new lesions. Per IWCLL criteria, CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. |
| Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | From the date of first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to disease progression or death from any cause (up to approximately 7 years) | DOR was defined as the interval from first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to earlier of first documentation of definitive disease progression or death from any cause. Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of longest diameters of all index lesions, no new lesions; VGPR: \>90% DFB in IgM, and other criteria for CR met; MR: ≥25% but \<50% DFB in IgM, no IFB in SPD of lesions, no new lesions. Per IWCLL criteria, CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC\>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. Disease progression: as defined in Outcome measure 1. DOR was analyzed using KM estimates. |
| Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | First dose date up to the last dose date plus 30 days (maximum: 78.4 months) | Hematology toxicity at any time postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test. ANC = absolute neutrophil count; Hb = hemoglobin; WBC = white blood cells |
Countries
Canada, United States
Participant flow
Recruitment details
Participants were enrolled at study sites in United States and Canada. The first participant was screened on 14 March 2013. The last study visit occurred on 30 January 2020.
Pre-assignment details
444 participants were screened.
Participants by arm
| Arm | Count |
|---|---|
| CLL: Entospletinib MM/SDD Participants with CLL, received original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 41 |
| FL: Entospletinib MM/SDD Participants with FL, received original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 41 |
| DLBCL: Entospletinib MM/SDD Participants with DLBCL, received original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 43 |
| MCL: Entospletinib MM/SDD Participants with MCL, received original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 39 |
| Non-FL iNHL: Entospletinib MM/SDD Participants with iNHL (ie, participants with LPL/WM, SLL, or MZL), received original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 49 |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 100 mg Participants with CLL, who were prior BCR inhibitor naive, received new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 19 |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg Participants with CLL, who were prior BCR inhibitor naive, received new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 21 |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg Participants with CLL, who were prior BCR inhibitor naive, received new formulation of entospletinib (SDD) 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 20 |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD Participants with CLL and simple progression (non-Richters), who were exposed to BTK inhibitor, received new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 33 |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD Participants with CLL and simple progression (non-Richters), who were exposed to PI3K inhibitor, received new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 8 |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD Participants with CLL, who transformed to Richters or Richters-like syndrome and were exposed to BTK inhibitor, received new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 6 |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD Participants with CLL, who transformed to Richters or Richters-like syndrome and were exposed to PI3K inhibitor, received new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib was continued until disease progression or unacceptable toxicity. | 3 |
| Total | 323 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 4 | 4 | 5 | 1 | 11 | 1 | 5 | 2 | 3 | 1 | 1 | 0 |
| Overall Study | Death | 1 | 0 | 5 | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Overall Study | Lack of Efficacy | 1 | 1 | 0 | 1 | 2 | 2 | 0 | 0 | 2 | 0 | 1 | 0 |
| Overall Study | Lost to Follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Non-Compliance With Study Drug | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Physician Decision | 3 | 2 | 4 | 4 | 5 | 5 | 5 | 2 | 6 | 0 | 0 | 1 |
| Overall Study | Progressive Disease | 30 | 26 | 25 | 30 | 23 | 9 | 8 | 13 | 18 | 5 | 3 | 1 |
| Overall Study | Specified Criteria for Withdrawal | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Study Terminated By Sponsor | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 1 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 6 | 4 | 0 | 5 | 1 | 3 | 1 | 2 | 1 | 1 | 1 |
Baseline characteristics
| Characteristic | CLL: Entospletinib MM/SDD | Total | CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 100 mg | Non-FL iNHL: Entospletinib MM/SDD | MCL: Entospletinib MM/SDD | DLBCL: Entospletinib MM/SDD | FL: Entospletinib MM/SDD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 73 years STANDARD_DEVIATION 9.6 | 70 years STANDARD_DEVIATION 11 | 73 years STANDARD_DEVIATION 12.7 | 70 years STANDARD_DEVIATION 8.6 | 61 years STANDARD_DEVIATION 9.7 | 71 years STANDARD_DEVIATION 7.4 | 69 years STANDARD_DEVIATION 9.4 | 72 years STANDARD_DEVIATION 10.9 | 69 years STANDARD_DEVIATION 11.1 | 70 years STANDARD_DEVIATION 9.8 | 71 years STANDARD_DEVIATION 11 | 67 years STANDARD_DEVIATION 14.8 | 66 years STANDARD_DEVIATION 11.7 |
| Race/Ethnicity, Customized Ethnicity Hispanic or Latino | 0 Participants | 16 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 4 Participants | 1 Participants | 2 Participants | 4 Participants |
| Race/Ethnicity, Customized Ethnicity Not Hispanic or Latino | 39 Participants | 298 Participants | 3 Participants | 6 Participants | 7 Participants | 30 Participants | 18 Participants | 19 Participants | 18 Participants | 44 Participants | 36 Participants | 41 Participants | 37 Participants |
| Race/Ethnicity, Customized Ethnicity Not Permitted | 2 Participants | 9 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Asian | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Race Black or African American | 3 Participants | 19 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants | 3 Participants | 2 Participants | 1 Participants | 2 Participants | 0 Participants | 3 Participants | 1 Participants |
| Race/Ethnicity, Customized Race Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Not Permitted | 1 Participants | 6 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Other | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Race White/Caucasian | 37 Participants | 291 Participants | 3 Participants | 5 Participants | 8 Participants | 27 Participants | 17 Participants | 19 Participants | 18 Participants | 45 Participants | 36 Participants | 37 Participants | 39 Participants |
| Region of Enrollment Canada | 0 participants | 15 participants | 0 participants | 0 participants | 0 participants | 2 participants | 0 participants | 1 participants | 0 participants | 5 participants | 3 participants | 4 participants | 0 participants |
| Region of Enrollment United States | 41 participants | 308 participants | 3 participants | 6 participants | 8 participants | 31 participants | 20 participants | 20 participants | 19 participants | 44 participants | 36 participants | 39 participants | 41 participants |
| Sex: Female, Male Female | 13 Participants | 121 Participants | 2 Participants | 2 Participants | 3 Participants | 9 Participants | 7 Participants | 7 Participants | 10 Participants | 18 Participants | 14 Participants | 15 Participants | 21 Participants |
| Sex: Female, Male Male | 28 Participants | 202 Participants | 1 Participants | 4 Participants | 5 Participants | 24 Participants | 13 Participants | 14 Participants | 9 Participants | 31 Participants | 25 Participants | 28 Participants | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 41 | 3 / 41 | 13 / 43 | 6 / 39 | 5 / 49 | 0 / 19 | 1 / 21 | 1 / 20 | 3 / 33 | 1 / 8 | 3 / 6 | 1 / 3 |
| other Total, other adverse events | 40 / 41 | 39 / 41 | 42 / 43 | 38 / 39 | 49 / 49 | 19 / 19 | 19 / 21 | 20 / 20 | 33 / 33 | 8 / 8 | 5 / 6 | 2 / 3 |
| serious Total, serious adverse events | 17 / 41 | 9 / 41 | 16 / 43 | 16 / 39 | 22 / 49 | 8 / 19 | 10 / 21 | 8 / 20 | 15 / 33 | 3 / 8 | 4 / 6 | 2 / 3 |
Outcome results
Primary
PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24
PFS rate was assessed by IRC and defined per standardized criteria (2007 Cheson criteria) (for NHL) and IWCLL criteria (for CLL), as the percentage of participants not experiencing definitive progression or death. Disease progression was defined per standardized criteria (2007 Cheson criteria) as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal IgM concentration or total serum IgM quantitation. Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL. PFS rate was analyzed using KM estimates.
Time frame: Week 24
Population: Participants in the full analysis set were analyzed. Only participants with CLL (including CLL, prior BCR inhibitor naive participants), FL, and non-FL iNHL were analyzed for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DLBCL: Entospletinib MM/SDD | PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | 66.9 percentage of participants |
| MCL: Entospletinib MM/SDD | PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | 51.5 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | 63.5 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | 64.2 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | 81.6 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24 | 84.2 percentage of participants |
Primary
Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16
PFS rate was assessed by Independent Review Committee (IRC) and defined per standardized criteria (2007 Cheson criteria) (for NHL) and International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (for CLL), as the percentage of participants not experiencing definitive progression or death. Disease progression was defined per standardized criteria as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal immunoglobulin M (IgM) concentration or total serum IgM quantitation. Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL. PFS rate was analyzed using Kaplan-Meier (KM) estimates.
Time frame: Week 16
Population: The Full Analysis Set included all enrolled participants who took at least one dose of study drug with treatment group designated according to the planned treatment. Only participants with CLL after BCR target therapy (including CLL non-Richters, and CLL Richters participants), SDD, MCL, and DLBCL were analyzed for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DLBCL: Entospletinib MM/SDD | Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | 3.6 percentage of participants |
| MCL: Entospletinib MM/SDD | Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | 63.9 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | 64 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | 100 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | 20 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16 | 50 percentage of participants |
Secondary
Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)
DOR was defined as the interval from first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to earlier of first documentation of definitive disease progression or death from any cause. Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of longest diameters of all index lesions, no new lesions; VGPR: \>90% DFB in IgM, and other criteria for CR met; MR: ≥25% but \<50% DFB in IgM, no IFB in SPD of lesions, no new lesions. Per IWCLL criteria, CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC\>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL. Disease progression: as defined in Outcome measure 1. DOR was analyzed using KM estimates.
Time frame: From the date of first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to disease progression or death from any cause (up to approximately 7 years)
Population: Participants in the Full Analysis Set with objective response were analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| DLBCL: Entospletinib MM/SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 22 months |
| MCL: Entospletinib MM/SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 7.6 months |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 7.5 months |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 19 months |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 26.9 months |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 14.9 months |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 17. months |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 8.1 months |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 11.3 months |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 2.7 months |
Secondary
Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)
ORR: percentage of participants with complete response (CR) or partial response (PR) (or very good PR \[VGPR\] or minor response \[MR\] for participants with LPL/WM). Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters of all index lesions, no new lesions; VGPR: \>90% decrease from baseline (DFB) in IgM, and other criteria for CR met; MR: ≥25% but \<50% DFB in IgM, no increase from baseline (IFB) in SPD of lesions, no new lesions. Per IWCLL, CR: lymphocytes (Ly) \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, absolute neutrophil count (ANC) \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, hemoglobin (Hb) \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL.
Time frame: From first dose date until first occurrence of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)
Population: Participants in the Full Analysis Set were analyzed.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DLBCL: Entospletinib MM/SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 53.7 percentage of participants |
| MCL: Entospletinib MM/SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 17.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 17.9 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 36.7 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 26.3 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 38.1 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 60.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 24.2 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 75.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 0 percentage of participants |
Secondary
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
A treatment-emergent Adverse Event (AE) was defined as an AE that occurs in the period from the first dose of study treatment to 30 days after the last dose of study treatment or leads to discontinuation of study treatment. Participants were assessed for AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.
Time frame: First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
Population: The Safety Analysis Set included all participants who took at least one dose of study drug with treatment group designated according to the actual treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DLBCL: Entospletinib MM/SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 97.7 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 97.4 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 95.2 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 100.0 percentage of participants |
Secondary
Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher
Hematology toxicity at any time postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test. ANC = absolute neutrophil count; Hb = hemoglobin; WBC = white blood cells
Time frame: First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
Population: Participants in the Safety Analysis Set were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 19.5 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 2.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 22.0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 14.6 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 34.1 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 85.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 14.6 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 14.6 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 7.3 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 7.3 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 2.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 17.1 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 12.2 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 12.2 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 9.8 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 4.9 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 4.9 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 9.8 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 12.2 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 48.8 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 4.7 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 4.7 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 14.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 9.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 15.4 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 5.1 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 7.7 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 5.1 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 10.3 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 12.8 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 2.6 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 22.4 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 16.3 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 6.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 6.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 6.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 4.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 22.4 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 6.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 22.4 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 10.2 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 12.2 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 52.6 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 94.7 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 15.8 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 10.5 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 15.8 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 5.3 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 14.3 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 9.5 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 14.3 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 19.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 9.5 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 85.7 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 42.9 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 20.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 20.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 15.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 25.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 40.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 20.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 10.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 70.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 6.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 63.6 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 12.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 9.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 27.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 15.2 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 30.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 9.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 12.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 12.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 6.1 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 25.0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 25.0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 25.0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 25.0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 37.5 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 12.5 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 33.3 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 33.3 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 33.3 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 16.7 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Anemia | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Neutrophils Decrease | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Leukocytosis | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Hb Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 ANC Decrease | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Platelet Count Decrease | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 ANC Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Leukocytosis | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Increase | 66.7 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Platelet Count Decrease | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Anemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 WBC Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Lymphocyte Count Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 3 Neutrophils Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher | Grade 4 Hb Increase | 0 percentage of participants |
Secondary
Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher
Serum chemistry toxicity at anytime postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase
Time frame: First dose date up to the last dose date plus 30 days (maximum: 78.4 months)
Population: Participants in the Safety Analysis Set were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 2.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 9.8 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 7.3 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 2.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 9.8 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 4.9 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 7.3 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 12.2 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 4.9 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 2.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 7.3 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 14.6 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 7.3 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 2.4 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| DLBCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 7.3 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 9.8 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 9.8 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 12.2 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 17.1 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 4.9 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 4.9 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 4.9 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 9.8 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 2.4 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 9.8 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| MCL: Entospletinib MM/SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 4.7 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 4.7 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 11.6 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 7.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 9.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 4.7 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 4.7 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 2.3 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 10.3 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 10.3 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 15.4 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 7.7 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 10.3 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 7.7 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 7.7 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 2.6 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 6.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 12.2 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 16.3 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 4.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 8.2 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 6.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 4.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 2.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 4.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 4.1 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 12.2 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 10.5 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 5.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 15.8 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 5.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 21.1 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 5.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 14.3 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 9.5 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 4.8 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 15.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 15.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 10.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 5.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 15.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 5.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 5.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 10.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 10.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 15.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 5.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 5.0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 15.2 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 6.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 18.2 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 12.1 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 3.0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 12.5 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 16.7 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 50.0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypokalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypophosphatemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyponatremia | 33.3 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 AST Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypophosphatemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALP Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoglycemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyponatremia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypermagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 ALT Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperkalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatinine Clearance Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 AST Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypoalbuminemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hyperglycemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine Clearance Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Indirect Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypomagnesemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypercalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypokalemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 ALT Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Creatine Kinase Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Direct Bilirubin Decrease | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hypernatremia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Blood Bilirubin Increase | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Creatinine | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 3 Hypocalcemia | 0 percentage of participants |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher | Grade 4 Hyperglycemia | 0 percentage of participants |
Secondary
Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)
TTR was defined as the interval from the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM). Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥ 50% reduction in SPD of the longest diameters of all index lesions, no new lesions; VGPR: \>90% DFB in IgM, and other criteria for CR met; MR: ≥25% but \<50% DFB in IgM, no IFB in SPD of lesions, no new lesions. Per IWCLL criteria, CR: Ly \<4\*10\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \>1.5\*10\^9/L, platelets ≥100\*10\^9/L, Hb \>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \>1500/μL, platelets ≥100,000/µL, Hb \>11 g/dL.
Time frame: From the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)
Population: Participants in the Full Analysis Set with available data were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DLBCL: Entospletinib MM/SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 3.2 months | Standard Deviation 2.15 |
| MCL: Entospletinib MM/SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 7.5 months | Standard Deviation 4.4 |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 4.6 months | Standard Deviation 4.65 |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 2.8 months | Standard Deviation 2.31 |
| CLL (Richters) Prior PI3K Inhibitor: Entospletinib SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 6.4 months | Standard Deviation 5.93 |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 200 mg | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 3.5 months | Standard Deviation 2.39 |
| CLL, Prior BCR Inhibitor Naive: Entospletinib SDD 400 mg | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 6.8 months | Standard Deviation 4.33 |
| CLL (Non-Richters) Prior BTK Inhibitor: Entospletinib SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 4.0 months | Standard Deviation 2.75 |
| CLL (Non-Richters) Prior PI3K Inhibitor: Entospletinib SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 3.4 months | Standard Deviation 1.82 |
| CLL (Richters) Prior BTK Inhibitor: Entospletinib SDD | Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL) | 1.8 months | Standard Deviation 0.05 |